DK132287A - Anvendelse af n-substitueret isobutyramid i racemisk (r,s)-form eller i venstredrejende optisk aktiv (s)-form eller et salt heraf til fremstilling af et laegemiddel mod obesitet - Google Patents

Anvendelse af n-substitueret isobutyramid i racemisk (r,s)-form eller i venstredrejende optisk aktiv (s)-form eller et salt heraf til fremstilling af et laegemiddel mod obesitet

Info

Publication number
DK132287A
DK132287A DK132287A DK132287A DK132287A DK 132287 A DK132287 A DK 132287A DK 132287 A DK132287 A DK 132287A DK 132287 A DK132287 A DK 132287A DK 132287 A DK132287 A DK 132287A
Authority
DK
Denmark
Prior art keywords
isobutyramide
racemic
substituted
salt
preparation
Prior art date
Application number
DK132287A
Other languages
English (en)
Other versions
DK132287D0 (da
Inventor
Brian Roy Holloway
Ralph Howe
Balbir Singh Rao
Donald Stribling
Original Assignee
Ici Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ici Plc filed Critical Ici Plc
Publication of DK132287D0 publication Critical patent/DK132287D0/da
Publication of DK132287A publication Critical patent/DK132287A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK132287A 1986-03-25 1987-03-13 Anvendelse af n-substitueret isobutyramid i racemisk (r,s)-form eller i venstredrejende optisk aktiv (s)-form eller et salt heraf til fremstilling af et laegemiddel mod obesitet DK132287A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868607312A GB8607312D0 (en) 1986-03-25 1986-03-25 Therapeutic agents

Publications (2)

Publication Number Publication Date
DK132287D0 DK132287D0 (da) 1987-03-13
DK132287A true DK132287A (da) 1987-09-26

Family

ID=10595167

Family Applications (1)

Application Number Title Priority Date Filing Date
DK132287A DK132287A (da) 1986-03-25 1987-03-13 Anvendelse af n-substitueret isobutyramid i racemisk (r,s)-form eller i venstredrejende optisk aktiv (s)-form eller et salt heraf til fremstilling af et laegemiddel mod obesitet

Country Status (6)

Country Link
US (1) US4937267A (da)
EP (1) EP0244080A3 (da)
JP (1) JPS62230722A (da)
DE (1) DE3709621A1 (da)
DK (1) DK132287A (da)
GB (2) GB8607312D0 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69100282T3 (de) † 1990-02-09 2001-01-11 Pharmacia & Upjohn Co., Kalamazoo Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
EP1394150B1 (en) 1999-02-24 2011-01-19 F. Hoffmann-La Roche AG 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
PT1385548E (pt) * 2001-01-26 2007-08-24 Schering Corp Combinações de um inibidor ou de inibidores de absorção de esteróis com agente (s) para o tratamento de doenças vasculares
SK9502003A3 (en) * 2001-01-26 2003-12-02 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
IL156445A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
WO2002058685A2 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
AR035533A1 (es) * 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
WO2002058733A2 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
ES2275007T3 (es) * 2001-05-25 2007-06-01 Schering Corporation Uso de derivados de azetidinona sustitudos en el tratamiento de la enfermedad de alzeimer.
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
CA2462200A1 (en) * 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
HUP0401501A3 (en) * 2001-09-21 2012-02-28 Schering Corp Treating or preventing vascular inflammation using pharmaceutical compositions containing sterol absorption inhibitor(s)
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
MXPA04002573A (es) * 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
WO2004043457A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
CA2517572C (en) 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
EP1601668B1 (en) 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
TWI280239B (en) 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
JP2007510659A (ja) * 2003-11-05 2007-04-26 シェーリング　コーポレイション 脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
DE602006011485D1 (de) 2005-09-23 2010-02-11 Hoffmann La Roche Neue dosierformulierung
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3961072A (en) * 1969-12-17 1976-06-01 Pfizer Inc. Phenoxypropanolamine therapeutic agents
US4083992A (en) * 1972-12-15 1978-04-11 Imperial Chemical Industries Limited Alkanolamine derivatives
GB1455116A (en) * 1972-12-15 1976-11-10 Ici Ltd Pharmaceutical compositions
GB1468156A (en) * 1973-07-19 1977-03-23 Ici Ltd Phenylethylamine derivatives
GB1458392A (en) * 1973-11-09 1976-12-15 Ici Ltd Optically-active 1-aryloxy-2,3-epoxypropane derivatives
FI65987C (fi) * 1973-12-12 1984-08-10 Ici Ltd Foerfarande foer framstaellning av nya terapeutiskt anvaendbara alkanolaminderivat
DE3061205D1 (en) * 1979-06-16 1983-01-05 Beecham Group Plc Secondary amines, their preparation and use in pharmaceutical compositions
US4618624A (en) * 1981-12-02 1986-10-21 American Cyanamid Company 3-amino-4-hydroxy(or alkoxy)phenethanolamine derivatives and pharmacologically-acceptable acid addition salts thereof for increasing the growth rate and/or improving the lean meat to fat ratio of warm-blooded animals
EP0085514A3 (en) * 1982-01-28 1984-02-29 Beecham Group Plc Compositions comprising a beta-antagonist and a beta-agonist, their preparation, and their use in treating obese humans and animals

Also Published As

Publication number Publication date
GB8607312D0 (en) 1986-04-30
DK132287D0 (da) 1987-03-13
EP0244080A2 (en) 1987-11-04
DE3709621A1 (de) 1987-10-08
US4937267A (en) 1990-06-26
JPS62230722A (ja) 1987-10-09
EP0244080A3 (en) 1990-05-16
GB2188234A (en) 1987-09-30
GB2188234B (en) 1991-01-02
GB8706946D0 (en) 1987-04-29

Similar Documents

Publication Publication Date Title
DK132287D0 (da) Anvendelse af n-substitueret isobutyramid i racemisk (r,s)-form eller i venstredrejende optisk aktiv (s)-form eller et salt heraf til fremstilling af et laegemiddel mod obesitet
DK368480A (da) Optisk aktive 1,4-dihydropyridiner fremgangsmaader til deres fremstilling og deres anvendelse som laegemidler
DK161668C (da) Anvendelse af phenyleddikesyrederivater til fremstillingen af et farmaceutisk middel til behandling af eller forebyggelse mod oejenbetaendelse
NO874632L (no) Cyclodextrinclathrater av carbacyclinderivater og deres anvendelse som legemiddel.
DK584089A (da) Quinuclidiner, deres anvendelse som laegemiddel og fremgangsmaade til deres fremstilling
DE3689571D1 (de) Halogenhaltige, optisch aktive Flüssigkristallverbindung und dieselbe enthaltende Flüssigkristallzusammensetzung.
DK349387D0 (da) Nitrofuranderivater samt fremgangsmaade til fremstilling deraf og anvendelse af forbindelserne som laegemiddel
DK166479C (da) Anvendelse af fluoxetin, norfluoxetin eller et farmaceutisk acceptabelt salt af fluoxetin eller norfluoxetin til fremstilling af et laegemiddel med anxiolytisk virkning
DK249181A (da) Acrylpolymerpraeparater fremgangsmaade til deres fremstilling og deres anvendelse isaer som midler mod kedelsten
DK593883A (da) Substituerede phenylsulfonyloxybenzimidazolcarbaminater, fremgangsmaade til deres fremstilling og deres anvendelse som laegemiddel
DK539087A (da) 4,5-dihydro- og 4,5,6,7-tetrahydro-pyrazolooe1,5-aaapyrimidiner, fremgangsmaader til deres fremstilling samt deres anvendelse som laegemidler
NO890187L (no) 2-(3,4-dihydroksyfenyl)etylaminer, deres fremstilling og anvendelse som farmasoeytika.
NO301767B1 (no) Salt av clavulansyre
NO874786D0 (no) Optisk aktive gyrasehemmere, deres fremstilling og anvendelse som antibiotika.
NO860907L (no) Heterocykliske sulfider og deres anvendelse som immunmodulatorer.
DK166210C (da) Krystallinske cephalosporin-hydrohalogenidsalte, fremgangsmaade til fremstilling deraf samt deres anvendelse som laegemidler
DK284688D0 (da) Beta-lactam-forbindelser, deres fremstilling og anvendelse som laegemidler
DK163639C (da) Synergistisk farmaceutisk blanding af vaevsplasminogenaktivator og et prostaglandin, farmaceutisk praeparat indeholdende blandingen samt anvendelse af blandingen til fremstilling af et laegemiddel mod blodpropper
NO863460D0 (no) Fremgangsmaate til fremstilling av 6-fenoksymetyl-4-hydroksy-tetrahydropyran-2-on, fremgangsmaate til deres fremstilling, og deres anvendelse som legemiddel, farmasoeytiske preparater og mellomprodukter.
NO875466L (no) Komplekser av vismut- eller antimonhalogenider og aminer,fremgangsmaate for fremstilling derav, samt polymerer inneholdende kompleksene som flammehemmende middel.
DK131187D0 (da) Anvendelse af aminosubstituerede benzoesyrer som laegemidler mod diarre og laegemidler paa grundlag af disse forbindelser
DK586284D0 (da) Quinoloncarboxylsyre-derivater, fremgangsmaade til fremstilling deraf samt anvendelse af saadanne derivater som laegemiddel
DK183886D0 (da) 4-phenylpropylindolderivater og deres salte og fremgangsmaade til deresfremstilling samt deres anvendelse som laegemidler
DK513188D0 (da) Aminosyreestre, deres fremstilling og anvendelse som laegemidler
DK176183D0 (da) Beta-lactam-antibiotika, fremgangsmade til fremstilling deraf samt deres anvendelse som laegemiddel

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment